Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

Keywords

IpilimumabMedicineImmunotherapyFood and drug administrationProstate cancerClinical trialCancerMelanomaOncologyCancer immunotherapyDrugInternal medicinePharmacologyCancer research

Affiliated Institutions

Related Publications

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert , Jacob Schachter , Georgina V. Long +19 more

The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced mela...

2015 New England Journal of Medicine 5661 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

Publication Info

Year: 2011
Type: review
Volume: 11
Issue: 11
Pages: 805-812
Citations: 630
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

630

OpenAlex

Cite This

APA Style

                            
                                
                                    Padmanee Sharma, 
                                
                                    Klaus W. Wagner, 
                                
                                    Jedd D. Wolchok
                                
                                et al.
                            
                            (2011). 
                            Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. 
                            Nature reviews. Cancer
                            , 11
                            (11)
                            , 805-812.
                            https://doi.org/10.1038/nrc3153
                        

Identifiers

DOI: 10.1038/nrc3153